Hairpin ribozyme-antisense RNA constructs can act as molecular lassos

Nucleic Acids Research

Volumn 36, Issue 21, 2008, Pages 6752-6766

  Dallas, Anne ^a   Balatskaya, Svetlana V ^a,c,d   Kuo, Tai Chih ^a,e   Ilves, Heini ^a   Vlassov, Alexander V ^a,f   Kaspar, Roger L ^a,g   Kisich, Kevin O ^a,h   Kazakov, Sergei A ^a   Johnston, Brian H ^a,b  

^a SomaGenics Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Codexis Inc ^*  (United States)

^d Taipei Medical University ^*  (United States)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f APPLIED BIOSYSTEMS   (United States)

^g TransDerm Inc   (United States)

^h NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; FAS ANTIGEN; HYBRID PROTEIN; LUCIFERASE; MESSENGER RNA; MESSENGER RNA PRECURSOR; RIBOZYME; RNA LASSO; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; ENZYME ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; REPORTER GENE; RNA BINDING; RNA STRUCTURE;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD95; BASE SEQUENCE; GENE EXPRESSION REGULATION; HUMANS; JURKAT CELLS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN BIOSYNTHESIS; RNA; RNA PRECURSORS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, ANTISENSE; RNA, CATALYTIC; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 57149090502     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn637     Document Type: Article

References (62)

1. Crooke,S.T. (2004) Antisense strategies. Curr. Mol. Med., 4, 465-487.
2. Dias,N. and Stein,C.A. (2002) Antisense oligonucleotides: Basic concepts and mechanisms. Mol. Cancer Ther., 1, 347-355.
3. Braasch,D.A. and Corey,D.R. (2002) Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry, 41, 4503-4510.
4. Heasman,J. (2002) Morpholino oligos: Making sense of antisense? Dev. Biol., 243, 209-214.
5. Kurreck,J. (2003) Antisense technologies. Improvement through novel chemical modfications. Eur. J. Biochem., 270, 1628-1644.
6. Toulme,J.J. (2001) New candidates for true antisense. Nat. Biotechnol., 19, 17-18.
7. Vester,B. and Wengel,J. (2004) LNA (locked nucleic acid): High-affinity targeting of complementary RNA and DNA. Biochemistry, 43, 13233-13241.
8. Chadwick,D.R. and Lever,A.M. (2000) Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther., 7, 1362-1368.
9. De Backer,M.D., Raponi,M. and Arndt,G.M. (2002) RNA-mediated gene silencing in non-pathogenic and pathogenic fungi. Curr. Opin. Microbiol., 5, 323-329.
10. Ji,Y., Yin,D., Fox,B., Holmes,D.J., Payne,D. and Rosenberg,M. (2004) Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol. Lett., 231, 177-184.
11. Ji,Y., Zhang,B., Van,S.F., Horn, Warren,P., Woodnutt,G., Burnham,M.K. and Rosenberg,M. (2001) Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science, 293, 2266-2269.
12. Varga,L.V., Toth,S., Novak,I. and Falus,A. (1999) Antisense strategies: functions and applications in immunology. Immunol. Lett., 69 217-224.
13. Yin,D. and Ji,Y. (2002) Genomic analysis using conditional phenotypes generated by antisense RNA. Curr. Opin. Microbiol., 5, 330-333.
14. Scherer,L.J. and Rossi,J.J. (2003) Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol., 21, 1457-1465.
15. Schubert,S. and Kurreck,J. (2004) Ribozyme- and deoxyribozyme-strategies for medical applications. Curr. Drug Targets, 5, 667-681.
16. Li,M. and Rossi,J.J. (2005) Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol., 309, 261-272.
17. Sano,M., Kato,Y., Akashi,H., Miyagishi,M. and Taira,K. (2005) Novel methods for expressing RNA interference in human cells. Methods Enzymol., 392, 97-112.
18. Zhang,Y.C., Taylor,M.M., Samson,W.K. and Phillips,M.I. (2005) Antisense inhibition: Oligonucleotides, ribozymes, and siRNAs. Methods Mol. Med., 106, 11-34.
19. Kazakov,S.A., Balatskaya,S.V. and Johnston,B.H. (2006) Ligation of the hairpin ribozyme in cis induced by freezing and dehydration. RNA, 12, 446-456.
20. Kisich,K.O., Freedland,S.J. and Erickson,K.L. (1997) Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro. Biochem. Biophys. Res. Commun., 236, 205-211.
21. Beaudry,D. and Perreault,J.P. (1995) An efficient strategy for the synthesis of circular RNA molecules. Nucleic Acids Res., 23, 3064-3066.
22. Harrison,B. and Zimmerman,S.B. (1984) Polymer-stimulated ligation: enhanced ligation of oligo- and polynucleotides by T4 RNA ligase in polymer solutions. Nucleic Acids Res., 12, 8235-8251.
23. Puttaraju,M., Perrotta,A.T. and Been,M.D. (1993) A circular trans-acting hepatitis delta virus ribozyme. Nucleic Acids Res., 21, 4253-4258.
24. Saville,B.J. and Collins,R.A. (1991) RNA-mediated ligation of self-cleavage products of a Neurospora mitochondrial plasmid transcript. Proc. Natl Acad. Sci. USA, 88, 8826-8830.
25. Jobling,S.A., Auron,P.E., Gurka,G., Webb,A.C., McDonald,B., Rosenwasser,L.J. and Gehrke,L. (1988) Biological activity and receptor binding of human prointerleukin-1 beta and subpeptides. J. Biol. Chem., 263, 16372-16378.
26. Shiraki,K., Tsuji,N., Shioda,T., Isselbacher,K.J. and Takahashi,H. (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl Acad. Sci. USA, 94, 6420-6425.
27. Saenger,W. (1984) Principles of Nucleic Acid Structure, Springer, New York.
28. Feldstein,P.A. and Bruening,G. (1993) Catalytically active geometry in the reversible circularization of 'mini-monomer' RNAs derived from the complementary strand of tobacco ringspot virus satellite RNA. Nucleic Acids Res., 21, 1991-1998.
29. Kazakov,S.A., Balatskaya,S.V. and Johnston,B.H. (1998) In Sarma,R. H. and Sarma,M. H. (eds), Structure, Motion, Interaction, and Expression of Biological Macromolecules, Adenine Press, Albany, New York, Vol. 2, pp. 155-161.
30. Pieper,S., Vauleon,S. and Muller,S. (2007) RNA self-processing towards changed topology and sequence oligomerization. Biol. Chem., 388 743-746.
31. Esteban,J.A., Banerjee,A.R. and Burke,J.M. (1997) Kinetic mechanism of the hairpin ribozyme. Identification and characterization of two nonexchangeable conformations. J. Biol. Chem., 272, 13629-13639.
32. Cheng,Y.K. and Pettitt,B.M. (1992) Stabilities of double- and triple-strand helical nucleic acids. Prog. Biophys. Mol. Biol., 58, 225-257.
33. Roberts,R.W. and Crothers,D.M. (1992) Stability and properties of double and triple helices: Dramatic e.ects of RNA or DNA backbone composition. Science, 258, 1463-1466.
34. Semerad,C.L. and Maher,L.J. 3rd (1994) Exclusion of RNA strands from a purine motif triple helix. Nucleic Acids Res., 22, 5321-5325.
35. Tafech,A., Bassett,T., Sparanese,D. and Lee,C.H. (2006) Destroying RNA as a therapeutic approach. Curr. Med. Chem., 13, 863-881.
36. Fedor,M.J. (2000) Structure and function of the hairpin ribozyme. J. Mol. Biol., 297, 269-291.
37. Wilson,T.J., Nahas,M., Ha,T. and Lilley,D.M. (2005) Folding and catalysis of the hairpin ribozyme. Biochem. Soc. Trans., 33, 461-465.
38. Komatsu,Y., Koizumi,M., Sekiguchi,A. and Ohtsuka,E. (1993) Cross-ligation and exchange reactions catalyzed by hairpin ribozymes. Nucleic Acids Res., 21, 185-190.
39. Komatsu, Y., Kanzaki, I., Koizumi, M. and Ohtsuka, E., (1995) Construction of new hairpin ribozymes with replaced domains. Nucleic Acids Symp. Ser., 223-224.
40. Berzal-Herranz,A. and Burke,J.M. (1997) Ligation of RNA molecules by the hairpin ribozyme. Methods Mol. Biol., 74, 349-355.
41. Joyce,G.F. (2004) Directed evolution of nucleic acid enzymes. Annu. Rev. Biochem., 73, 791-836.
42. Nilsson,M., Malmgren,H., Samiotaki,M., Kwiatkowski,M., Chowdhary,B.P. and Landegren,U. (1994) Padlock probes: Circularizing oligonucleotides for localized DNA detection. Science, 265, 2085-2088.
43. Nilsson,M., Barbany,G., Antson,D.O., Gertow,K. and Landegren,U. (2000) Enhanced detection and distinction of RNA by enzymatic probe ligation. Nat. Biotechnol., 18, 791-793.
44. Nielsen,P.E. (2000) Peptide nucleic acids: On the road to new gene therapeutic drugs. Pharmacol. Toxicol., 86, 3-7.
45. Bergeron,L.J., Ouellet,J. and Perreault,J.P. (2003) Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme. Curr. Med. Chem., 10 2589-2597.
46. Kool,E.T. (1991) Molecular recognition by circular oligonucleotides: increasing the selectivity of DNA binding. J. Am. Chem. Soc., 113, 6265-6266.
47. Kool,E.T. (1996) Circular oligonucleotides: New concepts in oligonucleotide design. Annu. Rev. Biophys. Biomol. Struct., 25 1-28.
48. Wang,S. and Kool,E.T. (1994) Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs. Nucleic Acids Res., 22, 2326-2333.
49. Tyagi,S. and Kramer,F.R. (1996) Molecular beacons: Probes that fluoresce upon hybridization. Nat. Biotechnol., 14, 303-308.
50. Eckstein,F. (2007) The versatility of oligonucleotides as potential therapeutics. Expert Opin. Biol. Ther., 7, 1021-1034.
51. Bohjanen,P.R., Colvin,R.A., Puttaraju,M., Been,M.D. and Garcia-Blanco,M.A. (1996) A small circular TAR RNA decoy speci.cally inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res., 24, 3733-3738.
52. Puttaraju,M. and Been,M.D. (1996) Circular ribozymes generated in Escherichia coli using group I self-splicing permuted intron-exon sequences. J. Biol. Chem., 271, 26081-26087.
53. Gryaznov, S. and Lloyd, D. (2000) Oligonucleotide clamps having diagnostic and therapeutic applications. United States Patent No. 6048974.
54. Husken,D., Asselbergs,F., Kinzel,B., Natt,F., Weiler,J., Martin,P., Haner,R. and Hall,J. (2003) mRNA fusion constructs serve in a general cell-based assay to profile oligonucleotide activity. Nucleic Acids Res., 31, e102.
55. Taylor,P.C., Williams,R.O. and Feldmann,M. (2004) Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr. Opin. Biotechnol., 15, 557-563.
56. Mercatante,D. and Kole,R. (2000) Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol. Ther. 85, 237-243.
57. Sierakowska,H., Agrawal,S. and Kole,R. (2000) Antisense oligonucleotides as modulators of pre-mRNA splicing. Methods Mol. Biol., 133, 223-233.
58. Skordis,L.A., Dunckley,M.G., Yue,B., Eperon,I.C. and Muntoni,F. (2003) Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl Acad. Sci. USA, 100, 4114-4119.
59. Vacek,M., Sazani,P. and Kole,R. (2003) Antisense-mediated redirection of mRNA splicing. Cell Mol. Life Sci., 60, 825-833.
60. Grunweller,A., Wyszko,E., Bieber,B., Jahnel,R., Erdmann,V.A. and Kurreck,J. (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res., 31, 3185-3193.
61. Miyagishi,M., Hayashi,M. and Taira,K. (2003) Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev., 13, 1-7.
62. Sohail,M. and Southern,E.M. (2000) Selecting optimal antisense reagents. Adv. Drug Deliv. Rev., 44, 23-34.